TherapeuticsMD (TXMD) Net Income towards Common Stockholders (2010 - 2026)
TherapeuticsMD's (TXMD) quarterly Net Income towards Common Stockholders came in at -$8000.0 in Q1 2026, up 52.94% YoY from -$5230.8 in Q1 2025, and down 14.29% on a QoQ basis from -$7000.0 in Q4 2025.
TherapeuticsMD (TXMD) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$8000.0 in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 52.94% year-over-year to -$8000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93000.0 (up 138.46% YoY) and the FY2025 annual result came in at $84000.0, down 35.88% from the prior year.
- Net Income towards Common Stockholders eased to -$8000.0 in Q1 2026, from -$7000.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $127.2 million in Q2 2022 to a low of -$31.1 million in Q1 2022.
- A 5-year average of $6.8 million and a median of -$7500.0 in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 398.12% — and 2025, when it slumped 122.67%.
- Tracing TXMD's Net Income towards Common Stockholders over 5 years: stood at $29.2 million in 2022, then plunged by 97.75% to $658000.0 in 2023, then sank by 79.03% to $138000.0 in 2024, then plunged by 105.07% to -$7000.0 in 2025, then decreased by 14.29% to -$8000.0 in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$8000.0 (Q1 2026), -$7000.0 (Q4 2025), and $102000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | TherapeuticsMD | 23.54 Mn | 14.35 Mn | - | 155,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9,000.00 |
| Mar 31, 2026 | -8,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | -17,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Sep 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -40,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | 658,000.00 |
| Sep 30, 2023 | -1.94 Mn |
| Mar 31, 2023 | -1.29 Mn |
| Dec 31, 2022 | 29.25 Mn |
| Sep 30, 2022 | -14.33 Mn |
| Jun 30, 2022 | 127.15 Mn |
| Mar 31, 2022 | -31.15 Mn |
| Dec 31, 2021 | 50.15 Mn |
| Sep 30, 2021 | -47.42 Mn |
| Jun 30, 2021 | -42.65 Mn |